Companies › Neuron23
1 active drug program in 1 registered trial: 1 Phase 2; Neurology; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| NEU-411 LRRK2 inhibitor | LRRK2 | Phase 2 | Parkinson Disease | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06680830 | NEU-411 | Phase 2 | Parkinson Disease | Neurology | Dec 2027 |
Syntara Aptinyx Bial R&D Investments SHINKEI Therapeutics NeuroTherapia
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.